NCT00101673View on ClinicalTrials.gov

Efficacy and Safety of Vildagliptin in Patients With Type 2 Diabetes With HbA1c 9-11%

PHASE3CompletedINTERVENTIONAL
Enrollment

251

Participants

Timeline

Start Date

March 31, 2004

Primary Completion Date

June 30, 2005

Study Completion Date

June 30, 2005

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

vildagliptin

Trial Locations (1)

Unknown

Novartis Pharmaceuticals, Basel

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY